Treatment of Obesity
The invention consists in a method of inducing lipid oxidation or increasing insulin sensitivity through the administration of a ligand which binds to the IL-6 receptor and signals via a gp130/LIF (leukemia inhibitory factor) receptor heterodimer. The chimeric ligand has the potential to be a highly effective therapy for obesity. Through this new methodology for increasing lipid oxidation there is no induction of an inflammatory state, no high concentrations of cytokine need to be used and no autoantibodies will be generated. The invention is particularly useful in treating subjects suffering from symptoms caused by obesity, excessive appetite and overweight, as well as obesity-associated metabolic disorders such as hypertension, osteoarthritis, type II diabetes, increased blood pressure, stroke and heart disease.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Superradiant atoms could push the boundaries of how precisely time can be measured
Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…
Ion thermoelectric conversion devices for near room temperature
The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…
Zap Energy achieves 37-million-degree temperatures in a compact device
New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…